SHUKLA SANJAY (President and CEO) purchased 17.2% of their position (20K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $36.1K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 6/3/2024ACC: 0000950170-24-067666
Officer· President and CEO
Since Feb 2019
+20K
Net shares
Net buyer
$36.1K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
20K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+20K
Price / share
$1.81
Trade value
$36.14K
% of position
17.2%
5/31/2024
116.55K→136.55K
Total
Net shares
+20K
Net value
$36.14K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/31/2024 | P · Purchase | +20K | $1.81 | $36.14K | 17.2% | 116.55K | 136.55K |
| Total | +20K | $36.14K | ||||||
Derivative Transactions0
No derivative transactions reported